ArticleFuture oncology (London, England)2025

LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC.

Jean-Pascal Machiels et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.